1. Viatris Pacira acquisition closes at $36.50 per share
Viatris Inc. (Nasdaq: VTRS) said on November 17, 2026 that it has completed the Viatris Pacira acquisition, buying Pacira BioSciences, Inc. (Nasdaq: PCRX) for $36.50 per share in cash. Holders tendered about 32,929,780 shares, or roughly 66.46% of those outstanding, and Viatris expects the business to add $90 million to $100 million in revenue through December 31, 2026.
The closing came less than six weeks after the transaction was first made public on October 8, 2026. It turns Pacira, a specialist in pain treatments that do not rely on opioids, from an independent listed company into a wholly owned subsidiary of a much larger pharmaceutical group, and it will end the trading of Pacira shares on the Nasdaq Global Select Market.
The sequence of events was compact. The tender offer expired late on November 16, the remaining conditions were cleared the following day, the tendered shares were accepted for payment, and the merger that made Pacira a subsidiary was carried out immediately afterward. All of it was announced together on November 17.
Viatris presented the deal as a step in building out its United States innovative medicines business. The company's own disclosure also acknowledges the usual uncertainty that follows any acquisition: that the benefits, synergies and efficiencies it anticipates may not be fully achieved.
2. How the tender offer played out
Shareholders of Pacira were asked to sell directly to the buyer rather than vote on a merger. Under the terms, each share was exchanged for $36.50 in cash, paid without interest and net of any applicable withholding taxes. The consideration was entirely cash, so former Pacira investors do not receive Viatris stock as part of the exchange.
The offer expired at one minute after 11:59 p.m. Eastern Time on November 16, 2026. Equiniti Trust Company, LLC, which acted as depositary for the offer, reported that approximately 32,929,780 shares had been validly tendered and not withdrawn by that deadline. That figure represented about 66.46% of Pacira's outstanding shares at the expiration time.
On November 17, every condition attached to the offer was either satisfied or waived. Peach Purchaser Sub Inc., a wholly owned subsidiary that Viatris used as the acquisition vehicle, then accepted the tendered shares for payment.
A tender offer of this kind is a common route for acquiring a public company. The buyer makes a public bid to purchase shares at a stated price for a limited period, and each investor decides individually whether to accept. A depositary collects the tendered shares and counts them, which is why the final tally in this case came from Equiniti rather than from either company.
The share count also shows how much support the bid attracted. Roughly two of every three Pacira shares were handed over voluntarily at the offered price before the deadline, which gave Viatris the ownership it needed to proceed to the second step without further shareholder action.
3. Why was there no Pacira shareholder vote?
No vote was needed because the deal was completed under Section 251(h) of Delaware's General Corporation Law, which lets a buyer that has acquired enough shares in a tender offer finish the merger without calling a stockholder meeting. After accepting the tendered shares, the purchaser subsidiary merged into Pacira on that basis.
The provision exists to shorten the second stage of a two-step acquisition. Without it, a buyer that already held a controlling majority after a tender offer would still have to organize a formal vote whose outcome was not in doubt, delaying payment to the remaining investors. With it, the tender offer and the merger can be completed in quick succession, as happened here on a single day.
Pacira is the surviving corporation in the merger and continues to exist as a legal entity, now wholly owned by Viatris. Peach Purchaser Sub, having served its purpose, was absorbed into it.
For shareholders, the practical consequence is speed and certainty rather than any change in value. The statute does not alter what investors are paid. It removes a procedural stage, so that those who did not take part in the tender offer are not left holding a minority stake in a controlled company while a meeting is scheduled.
4. What happens to Pacira shares that were not tendered?
Investors who did not tender receive the same price as those who did. Roughly a third of Pacira's shares were not submitted in the offer, and in the merger those shares were converted into the right to receive the offer price of $36.50 in cash.
In other words, holding out did not produce a different financial outcome. The remaining holders are cashed out at identical terms, and they no longer hold an equity interest in Pacira.
The stock itself will disappear from public markets. Pacira's shares are to be delisted from the Nasdaq Global Select Market, where they traded under the ticker PCRX. Once that takes effect, the company will no longer have publicly traded equity, and its results will be reported within those of its parent.
5. What Viatris says the deal delivers
Management's case for the purchase centers on a specific therapeutic area. Viatris Chief Executive Officer Scott A. Smith described the closing as "an important milestone" in carrying out the company's strategy to strengthen its US innovative medicines business. He said that bringing the two companies' portfolios and capabilities together establishes a leadership position in non-opioid pain management.
The financial guidance attached to the closing is narrow in scope. Viatris expects Pacira to contribute total revenues of between $90 million and $100 million for the remainder of 2026, a period that runs from the November 17 closing date through December 31. That is about six weeks of activity, so the range does not indicate what Pacira might add over a full year, and Viatris did not provide a full-year figure.
Smith's emphasis on capabilities as well as products is worth noting. A specialty medicine business depends on more than the drugs themselves; it also relies on the commercial and medical teams that work with hospitals and prescribers. Viatris is describing the purchase as a combination of two organizations in the same field, not only as the addition of a product line.
The company also listed the risk that it may not realize the expected benefits, synergies and efficiencies of the transaction. Statements of that kind are standard in acquisition announcements, but they describe a real feature of such deals: the price is paid at closing, while the returns depend on how well the acquired business is integrated afterward.
6. The two companies
Viatris describes itself as a global healthcare company whose mission is to help people around the world live healthier at every stage of life. Its portfolio spans four categories: generic drugs, value-added medicines, established brands and innovative medicines. The company is headquartered in the United States and operates global centers in Pittsburgh, Shanghai and Hyderabad, India. Its shares trade on Nasdaq under the symbol VTRS.
The breadth of that portfolio helps explain the logic of the purchase. Generic and established-brand medicines generally face steady pricing pressure, and companies with large portfolios of them often look to newer, differentiated products for growth. Viatris has identified its US innovative medicines business as the part of the company it wants to strengthen, and Pacira is being added to that unit.
Pacira BioSciences brings a focus on non-opioid pain management. Treatments in that category are intended to control pain without the opioid medicines that have been associated with dependence and misuse, which has made alternatives a priority for hospitals, physicians and health authorities in the United States. Until the closing, Pacira was a listed peer of Viatris; it is now one of its subsidiaries.
7. What it means for investors
For former Pacira shareholders, the outcome is settled. Their holdings have been exchanged, or will be exchanged, for a fixed cash amount per share, and any future performance of the pain-management business accrues to Viatris.
For Viatris shareholders, the picture is less complete. The company has gained a position in non-opioid pain management and a short-term revenue contribution it has quantified, but the larger questions remain open. The guidance covers only the final weeks of 2026, the full-year contribution has not been stated, and the effect of integration on costs and earnings will only become visible in later financial reports.
Because the consideration was paid in cash, the transaction also carries a straightforward trade-off. Existing Viatris holders are not diluted by new shares, but the company has committed cash to the purchase, and the return on that outlay rests on the acquired products performing as management expects.
Pacira's disappearance from the public market has a further consequence for anyone following the sector. Investors will no longer be able to assess the business through its own filings and share price. Its progress will have to be read from whatever detail Viatris chooses to break out within its own results.
8. What comes next
Three items are on the near-term calendar. The first is Viatris's regular quarterly dividend of $0.12 per share, which is payable on December 16, 2026, and is the first payout to follow the closing.
The second is the formal removal of Pacira's shares from the Nasdaq Global Select Market, which completes its transition from public company to subsidiary.
The third, and the most informative, is how Viatris reports Pacira's revenue for the period ending December 31, 2026. The company has set a range of $90 million to $100 million for those weeks, and the actual figure will offer the first measurable test of how the newly acquired business is performing under its new owner.
Beyond those dates, the longer test is the one Viatris itself has flagged: whether the anticipated benefits, synergies and efficiencies materialize. Evidence on that point will accumulate over several reporting periods, well after the closing-day figures have been confirmed.
